Pfizer Inc. (NYSE:PFE) reported fourth-quarter adjusted EPS of 63 cents, compared to 10 cents a year ago, beating the ...

Paxlovid sales hit $727M, up $3.9B YoY due to a revenue reversal, while Vyndaqel sales rose 60% to $1.55B, and Eliquis grew 14% to $1.83B. Get access to your new suite of high-powered trading ...

4Q Earnings: $410 million (loss of $3.4 billion 4Q24) ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

See "Use of Non-GAAP Financial Information". U.S. revenues increased 9% to $8.6 billion, primarily driven by higher demand for the Growth Portfolio and Eliquis, partially offset by the impact of ...

Andexxa (andexanet alfa) is approved for the reversal of anticoagulation by Factor Xa inhibitors – Bayer/Johnson & Johnson's Xarelto (rivaroxaban) and Pfizer/Bristol-Myers Squibb's Eliquis ...

We made great progress with commercial execution and achieved growth across our product portfolio for full-year 2024, including $3.4 billion in revenue from our legacy Seagen portfolio, as well as ...

But the same quarter last year included a revenue reversal tied to the planned return ... Pfizer said its blood thinner Eliquis, which is co-marketed by Bristol Myers Squibb, also helped drive ...

also has shown better than 90% inhibition of factor XI, with about 66% less bleeding compared with apixaban in patients with AF ... One catch is that, so far, there are no reversal agents for factor ...

Prior OAC treatment was collected, including those with an available specific reversal agent in our setting (vitamin K antagonists [VKA] and dabigatran [anti-FIIa]) and those without (rivaroxaban, ...